

**SUMMIT OVERVIEW / TENTATIVE PROGRAMME**

# PARITY 2027

The Global Biosimilars Summit

**21–23 September 2027 • The Logan Philadelphia, Philadelphia, USA**

One Logan Square, Philadelphia, PA 19103 • Around 200 senior delegates • Organised by Synerg Events

## About the Summit

PARITY 2027 is a three-day international summit for the people shaping the next phase of biosimilars: developers and manufacturers, CDMOs and supply partners, payers, licensing and business development leaders, investors, and regulatory, legal and policy specialists. Organised by Synerg Events, it is held at The Logan Philadelphia.

The programme moves from science to market to partnering. Day 1 covers science and regulation: analytical similarity and the totality of evidence, interchangeability designations and their commercial impact, and global regulatory harmonization across FDA, EMA and other approval pathways. Day 2 turns to manufacturing and market: CDMO selection and technology transfer, Medicare Maximum Fair Price, patent litigation under the BPCIA, physician and patient adoption, and market access. Day 3 is dedicated to partnering and outlook, with structured one-to-one partnering meetings running alongside sessions on value and patient access, licensing and investment.

## Tentative Programme

All six confirmed faculty members are included in proposed sessions. Speaker placements, formats and timings remain indicative and subject to change. Most talk titles are still to be confirmed.

**Speaker proposals: [sachin.sravan@synergevents.com](mailto:sachin.sravan@synergevents.com)**

### WHY PARTICIPATE

## Why Attend

Built around the decisions that move biosimilar programmes forward.

### A Single Focus on Biosimilars

Three days devoted to biosimilar science, manufacturing, market entry and partnering, rather than a general pharmaceutical meeting where biosimilars are one topic among many.

### Science to Market

Follow the path from analytical similarity and interchangeability through manufacturing partnerships, pricing and reimbursement to launch.

### Regulatory, Legal & Policy Dialogue

Hear regulatory, policy and BPCIA litigation perspectives on how approval pathways, patents and Medicare pricing shape launch timing and adoption.

### Structured Partnering

A dedicated day of pre-scheduled one-to-one partnering meetings between developers, CDMOs, licensing teams and investors.

## Who Attends

- Biosimilar developers and manufacturers (around 30% of delegates).
- CDMOs and supply partners (around 20%).
- Payers and market access leaders, licensing and business development executives, and investors.
- Regulatory, legal and policy specialists, including BPCIA litigation experts.



SUMMIT LEADERSHIP

# Conference Committee

CONFERENCE COMMITTEE

*Conference committee to be announced.*

PARTNERING / THURSDAY, 23 SEPTEMBER 2027

## One-to-One Partnering

A dedicated day of structured, pre-scheduled meetings

Day 3 is built around structured one-to-one partnering meetings that run throughout the day alongside the plenary sessions. Delegates browse attendee profiles, request the meetings that matter to them, and arrive with a schedule built around their priorities.

- |    |                         |                                                                                                      |
|----|-------------------------|------------------------------------------------------------------------------------------------------|
| 01 | <b>Browse profiles</b>  | Review attendee profiles across developers, CDMOs, payers, investors, regulators and licensing teams |
| 02 | <b>Request meetings</b> | Send meeting requests ahead of the summit                                                            |
| 03 | <b>Arrive scheduled</b> | Meet one-to-one on Day 3, alongside the Day 3 sessions                                               |

SUMMIT AT A GLANCE

## Three Days in Philadelphia

DAY 01 • TUE 21 SEPT

**Science & Regulation**

Analytical similarity •  
Interchangeability • Clinical design •  
Global regulatory harmonization (FDA,  
EMA and other pathways)

DAY 02 • WED 22 SEPT

**Manufacturing & Market**

CDMO selection • Medicare Maximum  
Fair Price • BPCIA litigation • Adoption  
• Market access

DAY 03 • THU 23 SEPT

**Partnering & Outlook**

One-to-one partnering • Value &  
patient access • Licensing &  
investment



DAY 01 / TUESDAY, 21 SEPTEMBER 2027

# Science & Regulation

Analytical similarity • Interchangeability • Clinical design • Global regulatory harmonization

|       |                                                                                                                                                                                                                                                                                                                                                                                    |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 08:30 | <b>Registration &amp; Networking Coffee</b>                                                                                                                                                                                                                                                                                                                                        |
| 09:00 | <b>Welcome &amp; Policy Keynote: Regulatory Convergence &amp; Divergence, US-EU</b><br>OPEN FOR SPEAKER PROPOSALS • US federal policy or FDA perspective<br>OPEN FOR SPEAKER PROPOSALS • European regulator perspective                                                                                                                                                            |
| 10:00 | <b>Networking Coffee Break</b>                                                                                                                                                                                                                                                                                                                                                     |
| 10:30 | <b>Panel: Analytical Similarity &amp; the Totality of Evidence</b><br><b>PROPOSED SPEAKERS</b><br><b>Giuseppe Randazzo</b><br>Vice President, Science and Regulatory Affairs, Association for Accessible Medicines<br>ADDITIONAL SPEAKER SOUGHT • Biosimilar developer analytical or CMC perspective<br>ADDITIONAL SPEAKER SOUGHT • Interchangeability/FDA perspective             |
| 11:20 | <b>Immunogenetics &amp; Antibody Sequence Analysis in Analytical Characterisation</b><br><b>PROPOSED SPEAKERS</b><br><b>Prof Sofia Kossida</b><br>Senior Member of the Institut Universitaire de France (IUF), Director of IMGT®, the international ImMunoGeneTics information system®, University of Montpellier<br><i>Talk title to be confirmed</i>                             |
| 12:00 | <b>Lunch &amp; Networking</b>                                                                                                                                                                                                                                                                                                                                                      |
| 13:00 | <b>Clinical Design for Biosimilar Development</b><br>OPEN FOR SPEAKER PROPOSALS • Clinical pharmacology or biosimilar developer clinical development perspective                                                                                                                                                                                                                   |
| 13:40 | <b>Panel: Interchangeability Designations &amp; Their Commercial Impact</b><br>OPEN FOR SPEAKER PROPOSALS • Interchangeability/FDA perspective, European regulator, payer/PBM or biosimilar developer                                                                                                                                                                              |
| 14:30 | <b>Networking Coffee Break</b>                                                                                                                                                                                                                                                                                                                                                     |
| 15:00 | <b>Panel: Global Regulatory Harmonization – Comparing FDA, EMA and Other Biosimilar Pathways</b><br><b>PROPOSED SPEAKERS</b><br><b>Dr Elena Guillén</b><br>MD, PhD, Clinical Pharmacologist, Senior Researcher, Leiden University Medical Center<br>ADDITIONAL SPEAKER SOUGHT • FDA perspective<br>ADDITIONAL SPEAKER SOUGHT • Other-regulator perspective (outside the US and EU) |
| 15:50 | <b>Fireside Chat: Regulatory &amp; Public Policy Priorities for Biosimilars</b><br>OPEN FOR SPEAKER PROPOSALS • Biosimilar developer regulatory and public policy perspective                                                                                                                                                                                                      |
| 16:40 | <b>Chair's Summary &amp; Close of Day 1</b> Sessions close 17:30                                                                                                                                                                                                                                                                                                                   |
| 18:00 | <b>Day 1 Welcome Reception</b> Tentative • Faculty, delegate and partner networking                                                                                                                                                                                                                                                                                                |

DAY 02 / WEDNESDAY, 22 SEPTEMBER 2027

# Manufacturing & Market

CDMO strategy • Medicare pricing • BPCIA litigation • Adoption • Market access

|       |                                                                                                                                                                                                                                                                                                                                                                                                |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 08:30 | <b>Registration &amp; Networking Coffee</b>                                                                                                                                                                                                                                                                                                                                                    |
| 09:00 | <b>Keynote: Market Access &amp; Medicare Reimbursement</b><br>INVITED KEYNOTE • SPEAKER TO BE CONFIRMED • US federal policy/CMS perspective                                                                                                                                                                                                                                                    |
| 10:00 | <b>Panel: Medicare Maximum Fair Price &amp; What It Means for Biosimilar Pricing and Adoption</b><br><b>PROPOSED SPEAKERS</b><br><b>Tom Newcomer</b><br>Senior Vice President, Head of US Commercial, Samsung Bioepis<br>ADDITIONAL SPEAKER SOUGHT • Payer/PBM perspective<br>ADDITIONAL SPEAKER SOUGHT • Hospital/health-system pharmacy perspective                                          |
| 10:50 | <b>Networking Coffee Break</b>                                                                                                                                                                                                                                                                                                                                                                 |
| 11:20 | <b>Panel: CDMO Selection Criteria &amp; Technology Transfer Best Practices</b><br>Panel, approximately 45 minutes, 3–4 speakers<br><b>PROPOSED SPEAKERS</b><br><b>Piyush Modi</b><br>Director, Regulatory Affairs, Amneal Pharmaceuticals<br>ADDITIONAL SPEAKER SOUGHT • CDMO leadership perspective<br>ADDITIONAL SPEAKER SOUGHT • Biosimilar developer manufacturing or technical operations |
| 12:10 | <b>Lunch &amp; Networking</b>                                                                                                                                                                                                                                                                                                                                                                  |
| 13:10 | <b>Panel: Patent Litigation Under the BPCIA</b><br>The patent dance, at-risk launches, settlement structures and how litigation shapes launch timing<br>OPEN FOR SPEAKER PROPOSALS • BPCIA litigation partner<br>OPEN FOR SPEAKER PROPOSALS • In-house legal counsel or biosimilar developer                                                                                                   |
| 14:10 | <b>Physician &amp; Patient Adoption Barriers: Switching, Nocebo &amp; Clinical Vigilance</b><br>OPEN FOR SPEAKER PROPOSALS • NHS pharmacy leadership<br>OPEN FOR SPEAKER PROPOSALS • Hospital/health-system pharmacy or clinician perspective                                                                                                                                                  |
| 15:00 | <b>Networking Coffee Break</b>                                                                                                                                                                                                                                                                                                                                                                 |
| 15:30 | <b>Patient Registries &amp; Post-Approval Evidence</b><br>OPEN FOR SPEAKER PROPOSALS • Registry lead, patient organisation or real-world evidence perspective                                                                                                                                                                                                                                  |
| 16:20 | <b>Chair's Summary &amp; Close of Day 2</b> Sessions close 17:00                                                                                                                                                                                                                                                                                                                               |
| 19:00 | <b>Day 2 Evening Networking Event</b> Tentative • Faculty, delegate and partner networking                                                                                                                                                                                                                                                                                                     |

DAY 03 / THURSDAY, 23 SEPTEMBER 2027

# Partnering & Outlook

One-to-one partnering • Value & patient access • Licensing & investment • Outlook

|             |                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 08:30       | <b>Registration &amp; Networking Coffee</b>                                                                                                                                                                                                                                                                                                                                                                             |
| 08:30–17:00 | <b>One-to-One Partnering Meetings</b><br>Pre-scheduled one-to-one meetings run throughout the day, alongside the sessions below                                                                                                                                                                                                                                                                                         |
| 09:00       | <b>Keynote: From Global Regulatory Divergence to Patient Access</b><br>Biosimilar regulation, value and patient access<br><b>PROPOSED SPEAKERS</b><br><b>Prof Jonathan H. Watanabe</b><br>Professor and Chair, Department of Clinical Pharmacy, Thomas A. Oliver Endowed Chair, Clinical Pharmacy, University of California, San Francisco<br><i>Working title: From Global Regulatory Divergence to Patient Access</i> |
| 09:50       | <b>Panel: BPCIA Litigation &amp; Patent Thickets</b><br>OPEN FOR SPEAKER PROPOSALS • BPCIA litigation partner or in-house legal counsel                                                                                                                                                                                                                                                                                 |
| 10:40       | <b>Networking Coffee Break</b>                                                                                                                                                                                                                                                                                                                                                                                          |
| 11:10       | <b>Panel: Licensing, Partnering &amp; Investor Perspectives</b><br>OPEN FOR SPEAKER PROPOSALS • Investor/BD licensing perspective<br>OPEN FOR SPEAKER PROPOSALS • Biosimilar developer business development                                                                                                                                                                                                             |
| 12:00       | <b>Lunch &amp; Partnering Meetings</b>                                                                                                                                                                                                                                                                                                                                                                                  |
| 13:00       | <b>One-to-One Partnering Meetings Continue</b> Afternoon partnering block                                                                                                                                                                                                                                                                                                                                               |
| 16:30       | <b>Closing Session: The Outlook for Biosimilars</b><br><b>SESSION LEAD / MODERATOR</b><br>With the summit organising team & faculty<br>OPEN FOR SPEAKER PROPOSALS • Moderator or closing perspective                                                                                                                                                                                                                    |
| 17:15       | <b>Summit Close</b>                                                                                                                                                                                                                                                                                                                                                                                                     |

**Sponsorship enquiries and speaker proposals:** [sachin.sravan@synergevents.com](mailto:sachin.sravan@synergevents.com)

Website: <https://pharmasynergevents.com/Parity2027/> • Registration: <https://pharmasynergevents.com/Parity2027/registration>

**TENTATIVE** • All speaker placements, timings and session formats are subject to change. Most talk titles are still to be confirmed.